In a previous study, 1 we demonstrated the ability of RIFLE ('Risk', 'Injury', 'Failure', 'Loss of kidney function', 'Endstage kidney disease') classification for acute kidney injury (AKI) 2 in predicting mortality of patients undergoing myeloablative haematopoietic cell transplantation (HCT). A more recent classification for AKI 3 based on RIFLE has been proposed by the Acute Kidney Injury Network (AKIN). This newly staging system (Table 1) differs from RIFLE as follows: it reduces the need for a baseline creatinine but does require at least two creatinine values within 48 h; AKI is defined as an abrupt (within 48 h) reduction in kidney function currently defined as an absolute increase in serum creatinine of more than or equal to 0.3 mg/dl (X26.4 mmol/l), a percentage increase in serum creatinine of more than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria 40.5 ml/kg per h for more than 6 h); 'Risk' maps to stage 1, but it also considers an increase in serum creatinine of more than or equal to 0.3 mg/dl (X26.4 mmol/l); 'Injury' and 'Failure' map to stages 2 and 3, respectively; stage 3 also includes patients who need renal replacement therapy irrespective of the stage at the time of renal replacement therapy; and the two outcome classes 'Loss' and 'End-stage kidney disease' have been removed. These modifications could confer greater sensitivity and specificity to this classification, however, to our knowledge, no studies have been published yet validating the AKIN classification. We sought to evaluate the capacity of the AKIN criteria to predict in-hospital mortality in myeloablative HCT by evaluating retrospectively all patients who received a myeloablative autologous or allogeneic HCT in our Hospital between January 2003 and December 2004. Patients were categorized on the basis of serum creatinine or urine output, or both, the criteria that led to the worst classification and the maximum AKIN possible. At least two serum creatinine values within 48 h were considered to define AKI stage. One-hundred and forty patients (86 men, mean age: 32.9714.69 years) were evaluated: 90 patients received an allogeneic HCT and 50 received an autologous HCT; 82 patients received peripheral blood stem cell transplantation and 58 a bone marrow graft. Acute kidney injury defined by AKIN occurred in 56 patients (40%): 39.3% were in stage 1, 21.4% in stage 2 and 39.3% in stage 3. Mortality rate was 15.7%, and increased significantly from normal renal function to stage 3 (Normal, 3.5%; stage 1, 9%; stage 2, 33.3%; and stage 3, 59%; Po0.0001). Forward stepwise multivariate regression analysis showed that stage 2 (odds ratio 10.13, 95% confidence interval 1.44-70.89, P ¼ 0.02), stage 3 (odds ratio 20.10, 95% confidence interval 3.72-108.4, Po0.0001), as well as the allogeneic HCT (odds ratio 9.25, 95% confidence interval 1.22-69.75, P ¼ 0.031) and sepsis (odds ratio 12.27, 95% confidence interval 3.11-48.31, Po0.0001) were associated with increased mortality, while stage 1 (odds ratio 1.32, 95% confidence interval 0.17-9.9, P ¼ 0.786) did not. Acute kidney injury defined by AKIN had good discriminative power on the in-hospital mortality rate (area under the receiver operating characteristic curve 0.77570.051, Po0.0001). In sum, the AKIN criteria enabled us to identify 40% of myeloablative HCT patients with various degrees of acute renal dysfunction, and seem an important tool to stratify these patients according to mortality risk. Modified from RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) criteria. 2 Acute kidney injury is defined as an abrupt (within 48 h) reduction in kidney function currently defined as an absolute increase in serum creatinine X0.3 mg/dl (X26.4 mmol/l), a percentage increase in serum creatinine X50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour for more than 6 h). a Individuals who receive renal replacement therapy (RRT) are considered to have met the criteria of stage 3 irrespective of the stage they are in at the time of RRT.
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